Current Strategy of Anti-arrhythmic Drug Therapy for Persistent Atrial Fibrillation-Reference-Cited by-同舟云学术

Current Strategy of Anti-arrhythmic Drug Therapy for Persistent Atrial Fibrillation

Published:2017 Issue:5 Volume:63 Page:373-377
ISSN:2187-9737
Container-title:Juntendo Medical Journal
language:en
Short-container-title:Juntendo Medical Journal

Author:

NAKAZATO YUJI¹

Affiliation:

1. Department of Cardiology, Juntendo University Urayasu Hospital

Publisher

The Jutendo Medical Journal

Link

https://www.jstage.jst.go.jp/article/jmj/63/5/63_373/_pdf

Reference24 articles.

1. 1) Fuster V, Rydén LE, Cannon DS, et al: ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 2006; 114: e257-354.

2. 2) Roy D, Talajic M, Dorian P, et al: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med, 2000; 342: 913-920.

3. 3) Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H: Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol, 2003; 92: 472-475.

4. 4) Nakazato Y, Yasuda M, Sasaki A, et al: Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J, 2005; 69: 44-48.

5. 5) JCS Joint Working Group: Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS2013). Circ J, 2014; 78: 1997-2021.